Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CELLO: Ocrelizumab in Radiologically Isolated Syndrome
NCT04877457Phase 4Terminated
- Sponsor
- Yale University
- Start
- Feb 2022
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ocrelizumab in radiologically isolated syndrome (RIS), sponsored by Yale University. Started Feb 2022; status: terminated.
02
Drugs
ocrelizumab
03
Conditions
radiologically isolated syndrome (RIS)
Beyond the preview
Go deeper on NCT04877457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04877457.